Get the Stockscreener App
8.57
1.90%
0.16
Fennec Pharmaceuticals Inc stock is traded at $8.57, with a volume of 76,875.
It is up +1.90% in the last 24 hours and up +10.44% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$8.41
Open:
$8.7
24h Volume:
76,875
Relative Volume:
0.96
Market Cap:
$236.53M
Revenue:
$21.25M
Net Income/Loss:
$-16.05M
P/E Ratio:
-14.05
EPS:
-0.61
Net Cash Flow:
$-17.14M
1W Performance:
-1.61%
1M Performance:
+10.44%
6M Performance:
+49.56%
1Y Performance:
+30.44%
1-Day Range:
$8.365
$8.76
1-Week Range:
$8.28
$8.9625
52-Week Range:
$3.96
$9.30
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
8.57 | 240.56M | 21.25M | -16.05M | -17.14M | -0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
What analysts say about Fennec Pharmaceuticals Inc. stockUnrivaled growth potential - jammulinksnews.com
Fennec Pharmaceuticals Inc. Stock Analysis and ForecastSkyrocketing returns - Autocar Professional
Is Fennec Pharmaceuticals Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
How To Trade (FENC) - news.stocktradersdaily.com
What drives Fennec Pharmaceuticals Inc. stock priceJaw-dropping returns - jammulinksnews.com
Why Fennec Pharmaceuticals Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
What makes Fennec Pharmaceuticals Inc. stock price move sharplyFree Elite Traders Group - Newser
(FENC) Long Term Investment Analysis - news.stocktradersdaily.com
Fennec Pharmaceuticals (TSE:FRX) Reaches New 52-Week High – Still a Buy? - Defense World
Long Term Trading Analysis for (FENC) - news.stocktradersdaily.com
Bank of America Corp DE Has $226,000 Stock Holdings in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec's Pedmarqsi gets nod from U.K. regulators - MSN
(FENC) Investment Analysis and Advice - news.stocktradersdaily.com
Insider Sell: Rosty Raykov Sells 10,000 Shares of Fennec Pharmac - GuruFocus
Insider Sell: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC) - GuruFocus
Fennec Pharmaceuticals elects board members, shareholders approve proposals By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals elects board members, shareholders approve proposals - Investing.com
Fennec Pharmaceuticals Approves Proposals at Shareholder Meeting - TipRanks
Fennec Announces Results of Annual Meeting - TradingView
Northern Trust Corp Sells 2,976 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
FENC Meeting Scheduled in Toronto Hosted by Craig-Hallum | FENC Stock News - GuruFocus
Indian Pharma Co. Hit With Patent Suit Over Fennec's Cancer Drug - Law360
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Shares Acquired by BNP Paribas Financial Markets - Defense World
Q2 EPS Estimate for Fennec Pharmaceuticals Raised by Analyst - Defense World
HC Wainwright Brokers Increase Earnings Estimates for FENC - Defense World
FY2026 Earnings Estimate for TSE:FRX Issued By HC Wainwright - Defense World
Research Analysts Offer Predictions for FENC FY2026 Earnings - Defense World
Fennec Pharmaceuticals (NASDAQ:FENC) Earns Buy Rating from HC Wainwright - Defense World
Don't Ignore The Insider Selling In Fennec Pharmaceuticals - simplywall.st
Fennec Pharmaceuticals (TSE:FRX) Reaches New 12-Month High on Insider Buying Activity - Defense World
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fennec Pharmaceuticals Inc Stock (FENC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RALLIS CHRIS A | Director |
Jul 07 '25 |
Sale |
8.71 |
1,119 |
9,746 |
54,792 |
| Raykov Rosty | Director |
Jul 03 '25 |
Sale |
8.61 |
10,000 |
86,100 |
60,670 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):